Novo Nordisk’s experimental drug ziltivekimab failed to meet its primary goal in a late‑stage clinical trial, according to the company’s latest report. The medication, a human monoclonal antibody designed to lower cardiovascular inflammation, did not significantly reduce the risk of major adverse cardiovascular events (MACE) compared to a placebo.
Results fall short of expectations
The trial’s data showed a hazard ratio of 0.99 for MACE, with a 95 % confidence interval ranging from 0.88 to 1.11. This range indicates no statistically significant difference between the treatment and the control group.
Martin Holst Lange, the executive vice president and chief scientific officer, said the drug produced the expected biological effect.
It did not translate into MACE benefits for the study population.
Novo Nordisk noted that the trial design required the drug to demonstrate at least a 20 % relative risk reduction at 95 % power. Achieving this threshold would have been necessary to move forward with the program.
No significant difference was observed.
Overall rates of adverse events and serious adverse events were similar to those seen with the placebo. A higher proportion of participants treated with ziltivekimab experienced serious infections, a side effect consistent with the drug’s IL‑6 inhibition mechanism.
Related: PROTAC Oral Exposure Challenge Demands Early Developer Action
These results mark a setback for the drug’s development timeline. Full results are scheduled to be presented at a scientific meeting in 2026, but the current data effectively halts progress on this specific indication.
Financial impact and stock reaction
The disappointment sent Novo Nordisk shares plummeting in Copenhagen trading, dropping by approximately 7.4 %. This represents the company’s largest single‑day decline since February 23, when another experimental treatment, CagriSema, failed to show non‑inferiority in a head‑to‑head trial.
Analysts at Citi and Jefferies suggested that the stock volatility appeared excessive given that ziltivekimab represents a relatively small portion of Novo’s overall portfolio.
Novo Nordisk clarified that this outcome will not impact its previously communicated adjusted operating profit outlook for the year. Instead, it will result in a non‑cash impairment charge during the third quarter.
The acquisition of ziltivekimab in 2020 was part of a broader strategy to expand Novo’s presence in cardiometabolic disease.
Novo Nordisk purchased Corvidia Therapeutics for an upfront payment of $725 million to secure the asset.
While this trial has concluded without success, Novo Nordisk intends to continue investigating the therapy in two other settings: a heart‑failure study known as HERMES and an acute heart‑attack trial called ARTEMIS. Data from these additional studies is expected in the first half of 2027.
